Bonus Material-16_SD1_Collop_2025

Pdf Summary

This Pulmonary Medicine Board Review presentation by Dr. Nancy Collop provides a comprehensive overview of sleep disorders, focusing primarily on obstructive sleep apnea (OSA), its physiology, diagnosis, epidemiology, consequences, and treatment. Sleep includes four stages—NREM stages N1, N2, N3 (light to deep sleep), and REM sleep, with REM sleep being most vulnerable to cardiovascular and respiratory irregularities.<br /><br />Respiration changes during sleep due to reduced voluntary control, decreased tidal volume, and diminished responsiveness to hypoxia, especially during REM. NREM sleep features stable breathing but increased upper airway resistance; REM shows irregular breathing and reduced muscle tone, increasing vulnerability for respiratory disorders.<br /><br />OSA is prevalent, affecting up to 1 billion globally, with 15-30% of U.S. men and 10-15% of women affected. Risk factors include age, male gender (especially under 50), menopause, high BMI, ethnicity, and genetic predisposition. OSA leads to cardiovascular disease, metabolic issues, neurocognitive deficits, daytime sleepiness, depression, and reduced quality of life. Daytime sleepiness, though common, is not present in all patients and correlates weakly with severity.<br /><br />Diagnosis relies on polysomnography (PSG), the gold standard, or home sleep apnea testing (HSAT) for uncomplicated cases. PSG uses EEG, airflow, effort, and oxygen saturation monitoring, while HSAT is limited but effective for moderate to severe OSA without significant comorbidities. Respiratory event scoring includes apneas, hypopneas, and respiratory effort-related arousals based on airflow and oxygen desaturation.<br /><br />Treatment prioritizes avoidance of alcohol and sedatives, positional therapy, weight loss (notably via bariatric surgery), and positive airway pressure (PAP) therapy—primarily CPAP and AutoPAP. CPAP adherence is variable but critical for benefit, with strategies to improve usage including education, addressing discomfort, and behavioral support. Oral appliances serve as alternatives mainly for mild to moderate OSA or CPAP intolerance. Surgical options like bariatric surgery, maxillomandibular advancement, and hypoglossal nerve stimulation offer promising results in select patients.<br /><br />Recent advances include FDA approval of tirzepatide for moderate to severe OSA with obesity, showing significant reductions in apnea-hypopnea index and body weight in trials. Pharmacologic options for residual sleepiness include modafinil, armodafinil, and solriamfetol, though no medication treats OSA itself.<br /><br />Key clinical points emphasize the high prevalence and underdiagnosis of OSA, especially in postmenopausal women and patients with comorbidities like resistant hypertension and atrial fibrillation. Effective diagnosis requires appropriate use of PSG or HSAT based on patient complexity, and initial treatment usually involves PAP therapy with follow-up to optimize adherence. Novel therapies and personalized approaches are emerging to improve outcomes.

Meta Tag

Concept Sleep Stage

Concept Sleep-Disordered Breathing

Concept Apnea-Hypopnea Index

Concept Obstructive Sleep Apnea

Concept Positive Airway Pressure

Concept Sleep Architecture

Keywords

obstructive sleep apnea

sleep disorders

polysomnography

home sleep apnea testing

positive airway pressure

CPAP

hypopnea

REM sleep

weight loss

tirzepatide

Sleep Stage

Sleep-Disordered Breathing

Apnea-Hypopnea Index

Obstructive Sleep Apnea

Positive Airway Pressure

Sleep Architecture